Comparative Pharmacology
Head-to-head clinical analysis: K TAB versus K 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K TAB versus K 10.
K-TAB vs K+10
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
Hypokalemia prevention and treatmentHypokalemia due to diuretic therapyDigitalis intoxication with hypokalemiaFamilial periodic paralysis (hypokalemic form)
Treatment and prevention of hypokalemiaDigitalis intoxication
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
None Documented
None Documented
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores.
Not metabolized; renally excreted.
Primarily excreted unchanged by the kidneys (90%); small amount excreted in feces. Not metabolized.
Renal (90% unchanged), fecal (10% as metabolites)
Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment.
80-90% bound to albumin and alpha1-acid glycoprotein
Potassium is not significantly bound to plasma proteins. It is essentially free in plasma (0% protein binding).
1-2 L/kg, indicating extensive tissue distribution
Vd: Approximately 0.5 L/kg (range 0.4-0.6 L/kg). This reflects distribution primarily into the extracellular fluid compartment, with subsequent slow equilibration into the intracellular space. Clinical meaning: The Vd is small, indicating that potassium remains largely in the ECF and is not extensively tissue-bound initially.
Oral: 92-100%
Oral: Potassium chloride solutions have bioavailability near 100% as they are completely absorbed. Solid oral formulations (tablets, capsules) have variable bioavailability depending on dissolution and release characteristics; enteric-coated products may have reduced bioavailability (80-90%). Intravenous: 100%.
For GFR <30 mL/min/1.73 m²: reduce dose by 50% or use alternative; monitor serum potassium closely. Avoid if GFR <10 mL/min/1.73 m² unless on dialysis.
GFR > 50 mL/min: no adjustment. GFR 10-50 mL/min: reduce dose by 50%; monitor serum potassium frequently. GFR < 10 mL/min: contraindicated unless serum potassium < 5.0 mEq/L and dialysis available.
No specific Child-Pugh adjustment. Use with caution in severe hepatic impairment due to risk of hyperkalemia from associated renal dysfunction.
No specific Child-Pugh dose adjustment required; monitor serum potassium and acid-base status due to risk of hyperkalemia in cirrhosis.
Weight-based: 1-2 mEq/kg/day orally in divided doses, not to exceed 20 mEq per dose; adjust based on serum potassium and renal function.
IV: 0.5-1 mEq/kg/dose up to 10 mEq per dose, infused at ≤0.5 mEq/kg/hour; maximum 1 mEq/kg/hour with cardiac monitoring. Oral: 1-2 mEq/kg/day in divided doses; maximum 3 mEq/kg/day. Use with caution in neonates.
Initiate at lower end of dosing range (e.g., 20 mEq/day) due to age-related decline in renal function; monitor potassium and renal function regularly.
Initiate at low end of adult dosing (e.g., 10-20 mEq/day oral); reduce infusion rate to ≤10 mEq/hour IV; monitor renal function and serum potassium closely due to age-related decreased GFR and increased sensitivity.
No FDA black box warning.
Potassium supplements can cause hyperkalemia and cardiac arrest. Use with extreme caution in patients with conditions predisposing to hyperkalemia. Monitor serum potassium levels and ECG regularly.
["Hyperkalemia risk, especially in renal impairment","Use with potassium-sparing diuretics increases hyperkalemia risk","Gastrointestinal lesions (ulceration, stricture) with wax-matrix tablets","Sudden cessation of high-dose potassium supplements may cause complications"]
Risk of hyperkalemia, especially with renal impairment, diabetes, or concurrent use of potassium-sparing diuretics or ACE inhibitors. Avoid rapid intravenous administration. Use with caution in patients with cardiac disease or those receiving digitalis.
["Hyperkalemia","Severe renal impairment (eGFR <30 mL/min)","Addison's disease","Untreated Addison's disease","Concomitant potassium-sparing diuretics","Adrenal insufficiency","Acidosis (metabolic or respiratory)","Chronic renal failure","Acute dehydration","Extensive tissue breakdown (e.g., severe burns)"]
Hyperkalemia, severe renal impairment with oliguria or azotemia, untreated Addison's disease, acute dehydration, heat cramps, and patients receiving potassium-sparing diuretics or aldosterone antagonists.
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, tomatoes) unless directed by your doctor. Do not use potassium-containing salt substitutes. Take with food to reduce gastric upset.
Avoid excessive intake of high-potassium foods (bananas, oranges, potatoes, spinach, tomatoes, avocados, dried fruits, beans, nuts) and salt substitutes containing potassium chloride, as these may increase the risk of hyperkalemia.
K-TAB (potassium chloride) is FDA pregnancy category C. No fetal risks demonstrated at standard doses; hyperkalemia may cause fetal arrhythmia. First trimester: no known teratogenicity. Second/third trimesters: excess potassium can cross placenta, potentially causing fetal cardiac effects if maternal levels elevated.
Potassium chloride (K+10) is FDA pregnancy category C. No adequate well-controlled studies in pregnant women. In first trimester, no evidence of teratogenicity from animal studies; however, high doses may cause maternal hyperkalemia with potential fetal effects due to altered maternal physiology. In second and third trimesters, risk primarily from maternal electrolyte imbalance. Avoid in severe hyperkalemia as it may cross placenta.
Potassium is normal constituent of breast milk. Supplementation unlikely to affect infant. M/P ratio approximately 1.1. Use with caution only if clearly needed, monitor infant for hyperkalemia signs.
Potassium is a normal component of human milk; supplementation unlikely to cause harm. M/P ratio not established but assumed to be ~1 due to passive distribution. Use caution with high doses (e.g., 10 mEq) as theoretical risk of hyperkalemia in infant if maternal levels elevated. Monitor infant for signs of hyperkalemia only if maternal dose high or renal impairment.
No specific dose adjustment required for pregnancy; titrate based on serum potassium and clinical response. Renal clearance increases in pregnancy, may require higher doses for hypokalemia; avoid overcorrection.
Increased plasma volume in pregnancy may reduce serum potassium concentration, potentially requiring higher doses to maintain normokalemia. However, dose adjustments should be guided by serum potassium levels rather than empirical changes. Monitor every 1-2 weeks initially. No specific pharmacokinetic studies; standard adult dose (10 mEq) may be insufficient in severe deficiency due to dilution, but caution to avoid hyperkalemia in cases of decreased renal function (common in preeclampsia).
Category C
Category C
K-TAB is an extended-release potassium chloride tablet. Do not crush or chew; ensure patients can swallow whole. Monitor serum potassium levels regularly, especially in renal impairment or with concurrent ACE inhibitors/ARBs. Slow intravenous administration is critical if IV route used; never give IV push. Hyperkalemia risk is highest with rapid infusion or in renal failure.
K+10 is potassium chloride 10 mEq for hypokalemia. Administer orally with food to reduce GI irritation. Never give IV push; must be diluted in appropriate IV fluid and infused at a rate not exceeding 10-20 mEq/hour. ECG monitoring is essential during IV administration due to risk of hyperkalemia and arrhythmias. Use with caution in renal impairment and in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics. Maximum oral dose: 40 mEq per day in divided doses unless severe deficiency.
Take this medication with food and a full glass of water to minimize gastrointestinal irritation.Swallow the tablet whole; do not crush, chew, or break it.If you have difficulty swallowing, tell your doctor; the tablet may cause esophageal ulceration.Do not take potassium supplements or salt substitutes without consulting your doctor.Seek immediate medical attention if you experience symptoms of hyperkalemia: muscle weakness, irregular heartbeat, or tingling in hands/feet.
Take this medication with a full glass of water or food to prevent stomach upset.Do not crush or chew extended-release tablets; swallow them whole.Do not use salt substitutes containing potassium without your doctor's approval.Report symptoms of hyperkalemia such as muscle weakness, tingling, or irregular heartbeat.Keep a consistent dietary potassium intake; avoid high-potassium foods unless directed by your physician.